| 68.42 -0.31 (-0.45%) | 04-16 12:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 81.84 | 1-year : | 95.59 |
| Resists | First : | 70.06 | Second : | 81.84 |
| Pivot price | 67.85  |
|||
| Supports | First : | 67.06 | Second : | 65.19 |
| MAs | MA(5) : | 68.71 |
MA(20) : | 67.38 |
| MA(100) : | 66.09 |
MA(250) : | 68.05 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 67.5 |
D(3) : | 74 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 76.55 | Low : | 60.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AZN ] has closed below upper band by 34.8%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.64 - 70.08 | 70.08 - 70.39 |
| Low: | 67.5 - 68.05 | 68.05 - 68.43 |
| Close: | 68.01 - 68.81 | 68.81 - 69.38 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Tue, 16 Apr 2024
AstraZeneca outperforms market despite losses on the day - MarketWatch
Tue, 16 Apr 2024
AstraZeneca Imfinzi long-term survival buoyed by new data - Seeking Alpha
Tue, 16 Apr 2024
Cerity Partners LLC Grows Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Tue, 16 Apr 2024
AstraZeneca upgrade (of sorts) by leading investment bank - Proactive Investors USA
Tue, 16 Apr 2024
Cerity Partners LLC Raises Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Mon, 15 Apr 2024
AstraZeneca PLC ADR outperforms market despite losses on the day - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,100 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 16.7 (%) |
| Shares Short | 7,660 (K) |
| Shares Short P.Month | 9,260 (K) |
| EPS | 1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.25 |
| Profit Margin | 13 % |
| Operating Margin | 16.9 % |
| Return on Assets (ttm) | 6.5 % |
| Return on Equity (ttm) | 15.6 % |
| Qtrly Rev. Growth | 7.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.77 |
| EBITDA (p.s.) | 4.84 |
| Qtrly Earnings Growth | 5.9 % |
| Operating Cash Flow | 10,340 (M) |
| Levered Free Cash Flow | 9,500 (M) |
| PE Ratio | 35.97 |
| PEG Ratio | 1.1 |
| Price to Book value | 2.7 |
| Price to Sales | 4.62 |
| Price to Cash Flow | 20.49 |
| Dividend | 0.99 |
| Forward Dividend | 0 |
| Dividend Yield | 1.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|